The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4·5 h of onset of symptoms

International Journal of Stroke

Volumn 5, Issue 4, 2010, Pages 325-328

  Amaro, Sergio ^a   Cánovas, David ^b   Castellanos, Mar ^c   Gállego, Jaime ^d   Martí Fèbregas, Joan ^e   Segura, Tomás ^f   Chamorro, Ángel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Hospital Universitari Parc Taulí   (Spain)

^c Neurology Service Hospital Univesitario Josep Trueta de Girona   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Acute stroke therapy; Cerebral infarction; Clinical trial; Neuroprotection; Protocols; RtPA

Indexed keywords

ALTEPLASE; BIOLOGICAL MARKER; LITHIUM CARBONATE; MANNITOL; MATRIX METALLOPROTEINASE; URIC ACID; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BRAIN DAMAGE; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; STROKE PATIENT; SYMPTOM; TREATMENT OUTCOME; AGED; BRAIN ISCHEMIA; CLINICAL PROTOCOL; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; POPULATION; SAMPLE SIZE; SOCIOECONOMICS; SPAIN; STROKE; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; POPULATION; RECOMBINANT PROTEINS; SAMPLE SIZE; SOCIOECONOMIC FACTORS; SPAIN; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URIC ACID; YOUNG ADULT;

EID: 77955154086     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2010.00448.x     Document Type: Article

References (12)

1. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-7. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
2. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985, 312:159-63.
3. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981, 78:6858-62.
4. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002, 33:1048-52.
5. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998, 53:613-25.
6. Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2007, 27:14-20.
7. Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke 2007, 38:2173-5.
8. Amaro S, Obach V, Cervera A. Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study. J Neurol 2009, 256:651-6.
9. Waring WS, Convery A, Mishra V, Shenkin A, Webb DJ, Maxwell SR. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci 2003, 105:425-30.
10. Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 2001, 38:365-71.
11. Recommendations for clinical trial evaluations of acute stroke therapies. Stroke 2001, 32:1598-606. Stroke Therapy Academic Industry Roundtable II.
12. Hacke W, Kaste M, Bluhmki E. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-29. ECASS Investigators.